Error message

  • Deprecated function: Optional parameter $feed_nid declared before required parameter $context is implicitly treated as a required parameter in include_once() (line 1439 of /local/drupal/imat/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $input declared before required parameter $form_state is implicitly treated as a required parameter in require_once() (line 12 of /local/drupal/imat/sites/all/modules/media/media.module).
×

Success Stories



Liquid Biopsy Success Stories

Liquid Biopsy Success StoriesThe ability to use a simple blood draw to develop a relatively non-invasive test for not only detecting the presence of cancer in a patient, but also determining the optimal treatment strategy is one of the white whales of cancer research. Seeking, validating, and clinically implementing markers that allow the ability to draw such conclusions from small samples of a patient’s blood is the focus of liquid biopsy technologies. Using liquid biopsies for monitoring a patient’s response to therapy or early signs of recurrence are possibilities that are already being practiced in clinics today. Listed below are examples of technologies supported by the IMAT program to enable an early detection and monitoring capability for cancer.


Liquid Biopsy 1: High-Definition Single Cell Analysis (HD-SCA)Liquid Biopsy 1: High-Definition Single Cell Analysis (HD-SCA)

“Each cancer today has tens of treatment options and we have over a thousand trials ongoing, there is no choice but to figure out how to manage treatment decisions with a comprehensive liquid biopsy.”

-Peter Kuhn, PhD, University of Southern California


Liquid Biopsy 2: NanoVelcroTMLiquid Biopsy 2: NanoVelcroTM

“Nanotechnology-enabled devices for non-invasive cancer detection.”

-Hsian-Rong Tseng, PhD, University of California, Los Angeles


Liquid Biopsy 3: Magnetic Ranking Cytometry (MagRC)Liquid Biopsy 3: Magnetic Ranking Cytometry (MagRC)

“Magnetic ranking cytometry allows the quantitative analysis of molecular markers in single circulating tumor cells. This is a powerful capability for liquid biopsy that will allow therapeutic targets to be tracked for treatment selection.”

-Shana Kelley, PhD, University of Toronto